Mitral valve repair

Allegheny General Hospital Receives Recognition as a Mitral Valve Repair Reference Center from the American Heart Association and the Mitral Foundation

Retrieved on: 
Friday, July 21, 2023
Heart, American Heart Association, Mitral valve replacement, Mitral valve repair, Survival, Cardiovascular disease, AGH, Allegheny General Hospital, Cardiology, Mitral valve, AHA, Hospital, AHN, Patient, Physician, Blood, Mortality, Allegheny Health Network, Northwestern University, Caregiver, Fatigue, Country, Nursing, Medical imaging, MD

PITTSBURGH, July 21, 2023 /PRNewswire-PRWeb/ -- Allegheny General Hospital (AGH), the flagship academic medical center of Allegheny Health Network (AHN), announced today it has once again received the Mitral Valve Repair Reference Center Award from the American Heart Association (AHA) and the Mitral Foundation for a demonstrated record of superior clinical outcomes resulting from evidence-based, guideline-directed degenerative mitral valve repair.

Key Points: 
  • Mitral valve repair is considered the gold-standard therapy for degenerative mitral valves and is generally preferred over mitral valve replacement since valve repair is associated with improved survival and fewer long-term complications.
  • The Mitral Valve Repair Reference Center award identifies hospitals with excellent processes and outcomes and gives patients and cardiologists the information necessary to make these important decisions when mitral valve surgery is required."
  • The Mitral Valve Repair Reference Center Award was developed to identify, recognize and promote the nation's recognized medical centers for mitral valve repair surgery.
  • For more information on the AHN mitral valve program, please call 412-359-8180 or visit ahn.org; for more on the American Heart Association and Mitral Foundation Mitral Valve Repair Reference Center Award, go to heart.org.

Tampa General Hospital Named to Becker's Hospital Review's 2023 List of 'Hospitals and Health Systems with Great Heart Programs'

Retrieved on: 
Monday, July 17, 2023
Becker's, Arrhythmia, Mitral valve repair, Postperfusion syndrome, Hospital, X-ray, Division, Patient, Electrophysiology, Health, News, Heart, Rib, CT, Business development, Heart failure, Leg, Artery, U.S. News & World Report, Tampa General Hospital, Diagnosis, Becker's Hospital Review, Coronary artery disease, Transesophageal echocardiogram, Vascular surgery, Becker, Partnership, Surgeon, Enhanced Primary Care Case Management Program, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Genetic counseling, MRI, TGH, Airline, Pharmaceutical industry, Dentistry, Medical imaging, Medical device, Quality, Tampa Bay, Cardiology

TAMPA, Fla., July 17, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) has been named one of the top hospitals and health systems in the U.S. delivering exemplary heart and vascular care, according to the 2023 Becker's Hospital Review's "100 Hospitals and Health Systems with Great Heart Programs" list.

Key Points: 
  • TAMPA, Fla., July 17, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) has been named one of the top hospitals and health systems in the U.S. delivering exemplary heart and vascular care, according to the 2023 Becker's Hospital Review's "100 Hospitals and Health Systems with Great Heart Programs" list.
  • Tampa General's inclusion on the list reflects the academic health system's commitment to providing comprehensive, individualized care for patients with a variety of heart and vascular conditions.
  • U.S. News & World Report also ranked Tampa General as "high performing" in Heart Attack and Heart Failure care for 2022-23.
  • Inclusion on the Becker's "100 Hospitals and Health Systems with Great Heart Programs" list is the latest among several high-profile recognitions for Tampa General Hospital, including:

Affluent Medical reports excellent safety and performance interim result of its Optimize II pivotal clinical study with Kalios TM , adjustable mitral ring, in the treatment of mitral regurgitation.

Retrieved on: 
Tuesday, July 26, 2022
Association, Pathology, Death, Physician, European Association for Cardio-Thoracic Surgery, Regulatory News Service, ISIN, Trial of the century, Wealth, CEO, Learning curve, Adrenal insufficiency, Degenerative disease, Associate, Mitral insufficiency, Safety, Classification, Medical University of Vienna, Recurrence, Company, Urinary incontinence, Patient, Heart, Life, Department, Heart failure, Medical school, Ticker, Mitral valve repair, NYHA, Pharmaceutical industry, Medical imaging, Telescopic sight, Medical device, Hospital, Cotignola, Medtech

Affluent Medical reports excellent safety and performance interim result of its Optimize II pivotal clinical study with Kalios TM , adjustable mitral ring, in the treatment of mitral regurgitation.

Key Points: 
  • Affluent Medical reports excellent safety and performance interim result of its Optimize II pivotal clinical study with Kalios TM , adjustable mitral ring, in the treatment of mitral regurgitation.
  • Affluent Medical reports excellent safety and performance interim result of its Optimize II pivotal clinical study with KaliosTM, adjustable mitral ring, in the treatment of mitral regurgitation
    Affluent Medical (ISIN code: FR0013333077 Ticker: AFME), a French medtech specializing in the international development and industrialisation of innovative medical prostheses, at a clinical stage, to treat cardiac mitral valve pathology and urinary incontinence, today reports excellent safety and performance interim result of its Optimize II pivotal study with KaliosTM adjustable mitral ring.
  • KaliosTM also would have the potential to improve the longer-term treatment of recurrent mitral regurgitation.
  • Today we report interim data of the first 16 patients with analysis completed in May 2022 from our pivotal Optimize II study.

Allegheny General Hospital Receives Recognition as a Mitral Valve Repair Reference Center from the American Heart Association and the Mitral Foundation

Retrieved on: 
Tuesday, September 28, 2021
Blood, AHA, Northwestern University, Mortality, National Association Medical Staff Services, Joint Commission, Network, Mitral valve, Fatigue, American College of Cardiology, Institute, Patient, Physician, American Heart Association, Cardiology, Caregiver, Hospital, American College, Society of Thoracic Surgeons, Heart, Allegheny Health Network, AHN, Death, Program, Mitral valve repair, Cardiovascular disease, Adrenal insufficiency, Research, Survival, Allegheny General Hospital, Gold Seal, AGH, Society, Medicine, Medical imaging, Pharmaceutical industry

PITTSBURGH, Sept. 28, 2021 /PRNewswire-PRWeb/ -- Allegheny General Hospital (AGH), the flagship academic medical center of Allegheny Health Network (AHN), announced today it has received the Mitral Valve Repair Reference Center Award from the American Heart Association (AHA) and the Mitral Foundation for a demonstrated record of superior clinical outcomes resulting from evidence-based, guideline-directed degenerative mitral valve repair.

Key Points: 
  • PITTSBURGH, Sept. 28, 2021 /PRNewswire-PRWeb/ -- Allegheny General Hospital (AGH), the flagship academic medical center of Allegheny Health Network (AHN), announced today it has received the Mitral Valve Repair Reference Center Award from the American Heart Association (AHA) and the Mitral Foundation for a demonstrated record of superior clinical outcomes resulting from evidence-based, guideline-directed degenerative mitral valve repair.
  • The recommended treatment for degenerative mitral valve disease is mitral valve reconstruction, as opposed to valve replacement with a bioprosthetic or mechanical valve since valve repair is associated with improved survival and fewer long-term complications.
  • The Mitral Valve Repair Reference Center Award was developed to identify, recognize and promote the nation's recognized medical centers for mitral valve repair surgery.
  • For more information on the AHN mitral valve program, please call 412-359-8180 or visit ahn.org; for more on the American Heart Association and Mitral Foundation Mitral Valve Repair Reference Center Award, go to heart.org.

Affluent Medical : Successful first post-operative adjustment of KaliosTM mitral ring.

Retrieved on: 
Thursday, September 16, 2021
Adrenal insufficiency, Degenerative disease, Regulatory News Service, NYHA, ISIN, Urinary incontinence, Classification, Patient, Mitral insufficiency, Aix-en-Provence, Rest, Prognosis, Mitral valve repair, Death, Laborde, Heart failure, Recurrence, Myocardial infarction, Medical device, Health insurance, KALIOS, AFFLUENT MEDICAL

Affluent Medical : Successful first post-operative adjustment of KaliosTM mitral ring.

Key Points: 
  • Affluent Medical : Successful first post-operative adjustment of KaliosTM mitral ring.
  • Affluent Medical (ISIN: FR0013333077 - ticker: AFME), a French medtech specialising in the international development and industrial scale-up of innovative medical prostheses, at a clinical stage, to treat urinary incontinence and cardiac mitral insufficiency, today announces the success of the first ever KaliosTM mitral ring adjustment on a patient suffering from post-operative recurrence of severe mitral insufficiency.
  • Following successful implantation of a KaliosTM adjustable mitral ring, a simple trace of residual leakage was observed in a patient, who was operated in August 2020 for major mitral insufficiency (4+) [1] ,following a myocardial infarction.
  • Affluent Medical's Chief Medical Officer Prof. Franois Laborde confirmed that the KaliosTM device was a major breakthrough in treating mitral regurgitation and its recurrence, which happens between 30% and 40% of the redo mitral incompetence as reported in the medical literature.

First Naturally-designed and Personalised Bioprosthesis SingValve Set to Revolutionise Heart Valve Surgery

Retrieved on: 
Thursday, July 1, 2021
Anatomy, Heart, Medical specialties, Cardiac surgery, Valvular heart disease, Mitral valve, Cardiology, Heart valve, Atrium, Mitral valve replacement, Mitral valve repair

As a personalised heart implant, based on pre-operative patient scans, the innovation has the potential to herald a new era of heart valve surgery.

Key Points: 
  • As a personalised heart implant, based on pre-operative patient scans, the innovation has the potential to herald a new era of heart valve surgery.
  • This newly-developed mitral valve bioprosthesis, named SingValve, mimics the appearance, form and physical properties of a human mitral valve.
  • SingValve was developed as a heart valve implant that is made for the individual patient.
  • The mitral valve is situated in the left heart chamber and separates the left atrium from the left heart ventricle.

Heart-Valve-Surgery.com Launches "Clinical Trials Education Platform" to Educate & Empower Heart Valve Patients

Retrieved on: 
Friday, June 4, 2021
Health sciences, Pharmaceutical industry, Health, Medicine, Cardiac surgery, Advertising, Patient recruitment, Recruitment, Clinical trial, Mitral valve repair

The new platform - which leverages novel algorithms and technologies - was developed to resolve several of the long-established obstacles that plague patient recruitment for heart valve clinical trials.

Key Points: 
  • The new platform - which leverages novel algorithms and technologies - was developed to resolve several of the long-established obstacles that plague patient recruitment for heart valve clinical trials.
  • A recent survey of 1,157 patients conducted by Heart-Valve-Surgery.com revealed that 73% of heart valve patients are "not very aware" of clinical trials.
  • The survey also found that while only 4% of patients have participated in a heart valve clinical trial 59% of heart valve patients would consider enrolling in a clinical trial.
  • Founded in 2006, Heart-Valve-Surgery.comis the largest educational resource and community of patients with heart valve disease.

Foldax Announces Successful First Human Use of Tria Biopolymer Mitral Heart Valve

Retrieved on: 
Tuesday, May 25, 2021
Health, Medical devices, Surgery, Research, Science, Cardiology, Biotechnology, Anatomy, Cardiac surgery, Heart, Mitral valve, Medical specialties, Heart valve, Valvular heart disease, Mitral valve repair, R. Ravi Kumar

Foldax , Inc. today announced the successful first-in-human use of its biopolymer Tria heart valve in surgically replacing a diseased mitral valve.

Key Points: 
  • Foldax , Inc. today announced the successful first-in-human use of its biopolymer Tria heart valve in surgically replacing a diseased mitral valve.
  • We are excited to be the first center in the world to implant the innovative Tria mitral valve as part of this research study.
  • In this first-in-man procedure, we saw an immediate improvement in the functionality of this patients heart valve once the valve was in place, said Dr. Heimansohn.
  • We thank Dr. Heimansohn and his skilled team at Ascension St. Vincent Hospital for their commitment to advancing cardiovascular medicine by successfully performing the first-in-man Tria mitral valve procedure, said Foldax CEO Frank Maguire.

Interventional Robotics Startup Moray Medical Boosts Seed Financing to $5.7 Million

Retrieved on: 
Monday, April 12, 2021
General Health, Professional services, Technology, Medical devices, Surgery, Science, Cardiology, Nanotechnology, Biotechnology, Finance, Other Technology, Health, Other Science, Cardiac surgery, Medical specialties, Anatomy, Heart, Mitral valve replacement, Mitral valve repair, Mitral valve, Heart valve

b'Moray Medical announced today that it has closed a total of $5.7 million in seed funding, an increase of $2.4 million compared to the initial raise reported on 01/27/2021.

Key Points: 
  • b'Moray Medical announced today that it has closed a total of $5.7 million in seed funding, an increase of $2.4 million compared to the initial raise reported on 01/27/2021.
  • Investors included 415 CAPITAL (lead), Heal Capital, as well as a number of prominent medtech entrepreneurs, such as Fred St. Goar, MD, inventor of the MitralClip\xe2\x84\xa2 transcatheter mitral valve repair (TMVR) system.\nThe company will use the funding to continue development of its CoralTMsystem, an innovative interventional robotics platform powered by microfluidics and an augmented reality (AR) digital user interface.
  • While the Coral platform promises to dramatically simplify a wide range of minimally invasive cardiovascular interventions, Moray Medical is initially focused on the rapidly growing transcatheter mitral valve repair (TMVR) market.\n\xe2\x80\x9cThere is no argument that transcatheter edge-to-edge repair (TEER), or clip therapy, is steadily evolving into the new clinical standard for heart valve repair.
  • However, the intricacy and learning curve required by currently marketed devices means that the overwhelming majority of sick patients are not receiving treatment,\xe2\x80\x9d said Mark Barrish, CEO and Co-Founder of Moray Medical.\n\xe2\x80\x9cOur Coral platform is designed to empower interventionalists at all skill levels not only to carry out these procedures but also to do so in a cost-efficient manner, with the goal of making certain that millions of additional sick patients who cannot be currently treated will get the life-saving intervention they need,\xe2\x80\x9d added Barrish.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210412005591/en/\n'

Cardiac Dimensions Welcomes Robert White to its Board of Directors

Retrieved on: 
Tuesday, April 6, 2021
Anatomy, Heart, Medical specialties, Organs, Regurgitation, Mitral valve, Cardiac surgery, Valvular heart disease, Mitral valve repair

KIRKLAND, Wash., April 6, 2021 /PRNewswire/ --Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the election of Robert Whiteas an independent director to its Board of Directors.

Key Points: 
  • KIRKLAND, Wash., April 6, 2021 /PRNewswire/ --Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure, today announced the election of Robert Whiteas an independent director to its Board of Directors.
  • "It's exciting to join a leader in the field whose innovative device is addressing the large unmet needs of patients suffering from heart failure," Mr. White commented.
  • Cardiac Dimensions is a leader in the development of innovative, minimally invasive treatments to address heart failure and related cardiovascular conditions.
  • Carnegie & Co. Cardiac Dimensions is headquartered in Kirkland, Washington and has operations in the United States, Australia and Germany.